124 related articles for article (PubMed ID: 35583188)
1. MEN1 silencing triggers the dysregulation of mTORC1 and MYC pathways in ER+ breast cancer cells.
Abou Ziki R; Teinturier R; Luo Y; Cerutti C; Vanacker JM; Poulard C; Bachelot T; Diab-Assaf M; Treilleux I; Zhang CX; Le Romancer M
Endocr Relat Cancer; 2022 Aug; 29(8):451-465. PubMed ID: 35583188
[TBL] [Abstract][Full Text] [Related]
2. Reduced menin expression leads to decreased ERα expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypes.
Teinturier R; Abou Ziki R; Kassem L; Luo Y; Malbeteau L; Gherardi S; Corbo L; Bertolino P; Bachelot T; Treilleux I; Zhang CX; Le Romancer M
Breast Cancer Res Treat; 2021 Dec; 190(3):389-401. PubMed ID: 34561764
[TBL] [Abstract][Full Text] [Related]
3. Impact of dual mTORC1/2 mTOR kinase inhibitor AZD8055 on acquired endocrine resistance in breast cancer in vitro.
Jordan NJ; Dutkowski CM; Barrow D; Mottram HJ; Hutcheson IR; Nicholson RI; Guichard SM; Gee JM
Breast Cancer Res; 2014 Jan; 16(1):R12. PubMed ID: 24457069
[TBL] [Abstract][Full Text] [Related]
4. Enhancer-Mediated Oncogenic Function of the Menin Tumor Suppressor in Breast Cancer.
Dreijerink KMA; Groner AC; Vos ESM; Font-Tello A; Gu L; Chi D; Reyes J; Cook J; Lim E; Lin CY; de Laat W; Rao PK; Long HW; Brown M
Cell Rep; 2017 Mar; 18(10):2359-2372. PubMed ID: 28273452
[TBL] [Abstract][Full Text] [Related]
5. MEN1 silencing aggravates tumorigenic potential of AR-independent prostate cancer cells through nuclear translocation and activation of JunD and β-catenin.
Luo Y; Vlaeminck-Guillem V; Baron S; Dallel S; Zhang CX; Le Romancer M
J Exp Clin Cancer Res; 2021 Aug; 40(1):270. PubMed ID: 34446068
[TBL] [Abstract][Full Text] [Related]
6. Reduced menin expression impairs rapamycin effects as evidenced by an increase in mTORC2 signaling and cell migration.
Razmara M; Monazzam A; Skogseid B
Cell Commun Signal; 2018 Oct; 16(1):64. PubMed ID: 30285764
[TBL] [Abstract][Full Text] [Related]
7. Combinatorial targeting of a chromatin complex comprising Dot1L, menin and the tyrosine kinase BAZ1B reveals a new therapeutic vulnerability of endocrine therapy-resistant breast cancer.
Salvati A; Melone V; Sellitto A; Rizzo F; Tarallo R; Nyman TA; Giurato G; Nassa G; Weisz A
Breast Cancer Res; 2022 Jul; 24(1):52. PubMed ID: 35850772
[TBL] [Abstract][Full Text] [Related]
8. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
[TBL] [Abstract][Full Text] [Related]
9. Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer.
Ribas R; Pancholi S; Rani A; Schuster E; Guest SK; Nikitorowicz-Buniak J; Simigdala N; Thornhill A; Avogadri-Connors F; Cutler RE; Lalani AS; Dowsett M; Johnston SR; Martin LA
Breast Cancer Res; 2018 Jun; 20(1):44. PubMed ID: 29880014
[TBL] [Abstract][Full Text] [Related]
10. MYC-binding lncRNA EPIC1 promotes AKT-mTORC1 signaling and rapamycin resistance in breast and ovarian cancer.
Wang Y; Zhang M; Wang Z; Guo W; Yang D
Mol Carcinog; 2020 Oct; 59(10):1188-1198. PubMed ID: 32810332
[TBL] [Abstract][Full Text] [Related]
11. microRNA regulation of mammalian target of rapamycin expression and activity controls estrogen receptor function and RAD001 sensitivity.
Martin EC; Rhodes LV; Elliott S; Krebs AE; Nephew KP; Flemington EK; Collins-Burow BM; Burow ME
Mol Cancer; 2014 Oct; 13():229. PubMed ID: 25283550
[TBL] [Abstract][Full Text] [Related]
12. Men1 disruption in Nkx3.1-deficient mice results in AR
Teinturier R; Luo Y; Decaussin-Petrucci M; Vlaeminck-Guillem V; Vacherot F; Firlej V; Bonnavion R; Abou Ziki R; Gherardi S; Goddard I; Gadot N; Bertolino P; Le Romancer M; Zhang CX
Oncogene; 2021 Feb; 40(6):1118-1127. PubMed ID: 33323967
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo.
Martin LA; Pancholi S; Farmer I; Guest S; Ribas R; Weigel MT; Thornhill AM; Ghazoui Z; A'Hern R; Evans DB; Lane HA; Johnston SR; Dowsett M
Breast Cancer Res; 2012 Oct; 14(5):R132. PubMed ID: 23075476
[TBL] [Abstract][Full Text] [Related]
14. Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc.
Rodrik V; Zheng Y; Harrow F; Chen Y; Foster DA
Mol Cell Biol; 2005 Sep; 25(17):7917-25. PubMed ID: 16107734
[TBL] [Abstract][Full Text] [Related]
15. Raloxifene inhibits menin-dependent estrogen receptor activation in breast cancer cells.
Imachi H; Yu X; Nishiuchi T; Miyai Y; Masugata H; Murao K
J Endocrinol Invest; 2011 Dec; 34(11):813-5. PubMed ID: 22322533
[TBL] [Abstract][Full Text] [Related]
16. Menin directly represses Gli1 expression independent of canonical Hedgehog signaling.
Gurung B; Feng Z; Hua X
Mol Cancer Res; 2013 Oct; 11(10):1215-22. PubMed ID: 23928057
[TBL] [Abstract][Full Text] [Related]
17. Ribozyme-mediated compensatory induction of menin-oncosuppressor function in primary fibroblasts from MEN1 patients.
Luzi E; Marini F; Tognarini I; Carbonell Sala S; Galli G; Falchetti A; Brandi ML
Cancer Gene Ther; 2010 Nov; 17(11):814-25. PubMed ID: 20706287
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of RPA2 promotes NF-κB activation in breast cancer by relieving the antagonistic function of menin on NF-κB-regulated transcription.
Chen CC; Juan CW; Chen KY; Chang YC; Lee JC; Chang MC
Carcinogenesis; 2017 Feb; 38(2):196-206. PubMed ID: 28007956
[TBL] [Abstract][Full Text] [Related]
19. Resistance to everolimus driven by epigenetic regulation of MYC in ER+ breast cancers.
Bihani T; Ezell SA; Ladd B; Grosskurth SE; Mazzola AM; Pietras M; Reimer C; Zinda M; Fawell S; D'Cruz CM
Oncotarget; 2015 Feb; 6(4):2407-20. PubMed ID: 25537515
[TBL] [Abstract][Full Text] [Related]
20. The mammalian target of rapamycin complex 1 (mTORC1) in breast cancer: the impact of oestrogen receptor and HER2 pathways.
Jerjees DA; Negm OH; Alabdullah ML; Mirza S; Alkaabi M; Hameed MR; Abduljabbar R; Muftah A; Nolan CC; Green AR; Tighe PJ; Band V; Ellis IO; Rakha EA
Breast Cancer Res Treat; 2015 Feb; 150(1):91-103. PubMed ID: 25701120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
